hVIVO plc (LSE:HVO) has been awarded a £6 million contract by a clinical-stage biopharmaceutical company to conduct an influenza human challenge trial evaluating a monoclonal antibody treatment. The study will use hVIVO’s proprietary Influenza Human Challenge Study Model and will be carried out at the company’s specialist facilities in Canary Wharf, London. Trial activity is scheduled to begin in 2026, with associated revenues expected to be recognised across both 2026 and 2027.
Contract strengthens revenue visibility and service offering
The agreement enhances hVIVO’s forward revenue visibility and further demonstrates the strength of its integrated clinical development platform. The company said the project will utilise its full-service capabilities, including volunteer recruitment through FluCamp, clinical trial execution and specialist virology services. Management believes the contract highlights the increasing demand for rapid and efficient infectious disease research solutions as healthcare systems continue to face pressure from seasonal influenza outbreaks.
Integrated model supports position in challenge trial market
hVIVO continues to strengthen its position as a leading provider of human challenge trials by combining consulting, clinical development, laboratory services and quarantine facilities within a single platform. Its proprietary challenge models, together with its large volunteer database and dedicated research infrastructure, have enabled the group to work with many of the world’s largest biopharmaceutical companies in accelerating vaccine and therapeutic development programmes.
Financial pressures remain despite improving demand trends
The company’s outlook is currently weighed down by weaker recent financial performance, including losses, negative gross profit and pressure on cash flow generation. However, these challenges are partly offset by moderately positive technical trading indicators and management commentary suggesting improving demand and a strengthening commercial pipeline. Liquidity levels and the timing of future contract bookings remain important factors for investors to monitor in the near term.
More about hVIVO plc
hVIVO plc is a UK-based clinical development partner specialising in human challenge trials and infectious disease research. The company works with seven of the world’s ten largest biopharmaceutical groups, providing services ranging from preclinical consulting through to Phase II trials and specialist laboratory analysis. Through its integrated operating model, hVIVO combines clinical trial services, quarantine facilities, virology laboratories and volunteer recruitment operations in the UK and Germany to accelerate the development of vaccines and therapeutics, particularly in respiratory and infectious diseases.
Leave a Reply